#Norway #Oslo #Navamedic ASA #Antibiotics Portfolio #Flexilev Product

Navamedic ASA Financial Report for Q2 and H1 2025

Introduction
In its recent financial report, Navamedic ASA, a Nordic pharmaceutical company listed on the Oslo Stock Exchange (OSE: NAVA), has unveiled its results for the second quarter and the first half of 2025. The report highlights a significant evolution in their business dynamics, showcasing resilience despite challenges.

Financial Overview
Navamedic ASA recorded revenues of NOK 269.3 million during the first half of 2025, demonstrating a slight decrease from NOK 277.2 million in the same period in 2024. However, when excluding a notable milestone license fee of NOK 22.7 million from Orion Corporation received last year, revenues marked a commendable increase of 5.8% year-over-year. The gross margin also showed improvement, rising to 37.3% from 37.0% in Q2 2024, indicating the company's ability to maintain profitability while navigating a competitive market.

Driving Factors Behind Growth
The surge in revenue can be attributed primarily to the hospital segment, notably the company's antibiotics portfolio, which experienced a spectacular year-over-year growth of 48.4%. Navamedic's CEO, Kathrine Gamborg Andreassen, commented on the encouraging quarterly results, stating that their strategic investments over the past year are beginning to yield positive results. She specifically highlighted that the 5.8% revenue growth was significantly bolstered by successful Nordic tender wins for their antibiotics range. Additionally, several products within the Prescription Drugs segment, such as Imdur®, also performed exceptionally well.

Moreover, the approval of the medical device OraFID® for its Parkinson's disease treatment, Flexilev®, has positioned the company for further innovations in healthcare. Flexilev® has seen sales growth of 4.8% year-over-year, contributing to demonstrating Navamedic's commitment to specialized medical solutions.

Segment Performance
Within the Prescription Drugs category, sales of Imdur® skyrocketed with an impressive 101.0% increase year-over-year, while Mysimba® faced a challenging period, posting a 12% decrease in year-to-date revenues. In the Consumer Health segment, results were mixed, with product revenues fluctuating: Modifast saw a slight decline of 1.1%, whereas Eroxon® reported a significant revenue increase of 10.7%.

Outlook and Future Initiatives
Moving forward, Navamedic maintains a positive outlook, continuing to explore growth opportunities and reaffirming their ambition of achieving NOK 1 billion in revenue in the mid-term. Andreassen emphasized that the past six months have been pivotal due to effective execution across various initiatives, from product acquisitions to impactful marketing campaigns.

Although some initiatives may take time to reflect in financial results, the company is optimistic about its future, having established a robust foundation for sustained growth. They anticipate that planned acquisitions, such as that of dne pharma, will further enrich their growth trajectory.

Company Presentation and Additional Information
Navamedic is set to present the results live, providing insights into their strategic initiatives and financial health, at 08:30 on the day of the release. Interested parties can access the live presentation online.

For more information about Navamedic ASA and its commitment to transforming health care solutions, please visit Navamedic's website.

Conclusion
In conclusion, while the results of the first half of 2025 reflect both challenges and triumphs for Navamedic ASA, the key growth figures and forthcoming innovations position the company favorably for continued success within the Nordic pharmaceutical landscape. Navamedic remains dedicated to enhancing the health quality of individuals through reliable health solutions, solidifying their standing as a significant player in the industry.